Flexion Therapeutics Inc (FLXN):企業の財務・戦略的SWOT分析

【英語タイトル】Flexion Therapeutics Inc (FLXN) - Financial and Strategic SWOT Analysis Review

GlobalDataが出版した調査資料(DATA904C5338)・商品コード:DATA904C5338
・発行会社(調査会社):GlobalData
・発行日:2018年9月
・ページ数:46
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Flexion Therapeutics Inc (FLXN) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Flexion Therapeutics Inc (Flexion) develops and commercializes pain therapies. The company’s pipeline is focused on indications that includes osteoarthritis knee pain (repeat administration), osteoarthritis knee synovial inflammation, bilateral knee osteoarthritis pain shoulder and hip osteoarthritis pain and inflammatory conditions. The company’s marketed product includes Zilretta which is the first and only extended-release, intra-articular therapy for patients confronting osteoarthritis-related knee pain. Flexion employs its proprietary microsphere technology to combine TA with a PLGA matrix for formulating Zilretta. It offers anti-inflammatory and analgesic therapies for osteoarthritis. Flexion is headquartered in Burlington, Massachusetts, the US.

Flexion Therapeutics Inc Key Recent Developments

Aug 07,2018: Flexion Therapeutics reports second-quarter 2018 financial results and recent business highlights
Jun 21,2018: Flexion Therapeutics Named one of Boston Business Journal’s Best Places to Work for the Second Year in a Row
May 08,2018: Flexion Therapeutics Reports First-Quarter 2018 Financial Results and Recent Business Highlights
May 07,2018: Flexion Therapeutics Appoints David Arkowitz As Chief Financial Officer
Mar 08,2018: Flexion Therapeutics Reports Full Year 2017 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Flexion Therapeutics Inc – Key Facts 6
Flexion Therapeutics Inc – Key Employees 7
Flexion Therapeutics Inc – Key Employee Biographies 8
Flexion Therapeutics Inc – Major Products and Services 9
Flexion Therapeutics Inc – History 10
Flexion Therapeutics Inc – Company Statement 11
Flexion Therapeutics Inc – Locations And Subsidiaries 12
Head Office 12
Other Locations & Subsidiaries 12
Section 2 – Company Analysis 13
Company Overview 13
Flexion Therapeutics Inc – Business Description 14
R&D Overview 14
Flexion Therapeutics Inc – Corporate Strategy 15
Flexion Therapeutics Inc – SWOT Analysis 16
SWOT Analysis – Overview 16
Flexion Therapeutics Inc – Strengths 16
Flexion Therapeutics Inc – Weaknesses 17
Flexion Therapeutics Inc – Opportunities 18
Flexion Therapeutics Inc – Threats 19
Flexion Therapeutics Inc – Key Competitors 20
Section 3 – Company Financial Ratios 21
Financial Ratios – Capital Market Ratios 21
Financial Ratios – Annual Ratios 22
Performance Chart 24
Financial Performance 24
Financial Ratios – Interim Ratios 25
Financial Ratios – Ratio Charts 26
Section 4 – Company’s Lifesciences Financial Deals and Alliances 27
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 28
Flexion Therapeutics Inc, Recent Deals Summary 29
Section 5 – Company’s Recent Developments 30
Aug 07, 2018: Flexion Therapeutics reports second-quarter 2018 financial results and recent business highlights 30
Jun 21, 2018: Flexion Therapeutics Named one of Boston Business Journal’s Best Places to Work for the Second Year in a Row 32
May 08, 2018: Flexion Therapeutics Reports First-Quarter 2018 Financial Results and Recent Business Highlights 33
Dec 12, 2017: Flexion Therapeutics Announces Appointment of Scott Kelley, M.D. as CMO 35
Dec 11, 2017: Flexion Therapeutics Announces Appointment of Scott Kelley, M.D. as Chief Medical Officer 36
Nov 06, 2017: Flexion Therapeutics Reports Third-Quarter 2017 Financial Results and Recent Business Highlights 37
Aug 08, 2017: Flexion Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights 38
Jun 28, 2017: Flexion Therapeutics appoints new senior vice president, general counsel and secretary 39
May 04, 2017: Flexion Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Highlights 40
Apr 07, 2017: Flexion Therapeutics Announces Appointment of Yamo Deniz, MD, as Chief Medical Officer 41
Section 6 – Appendix 42
Methodology 42
Ratio Definitions 42
About GlobalData 46
Contact Us 46
Disclaimer 46

List of Tables
Flexion Therapeutics Inc, Key Facts 6
Flexion Therapeutics Inc, Key Employees 7
Flexion Therapeutics Inc, Key Employee Biographies 8
Flexion Therapeutics Inc, Major Products and Services 9
Flexion Therapeutics Inc, History 10
Flexion Therapeutics Inc, Subsidiaries 12
Flexion Therapeutics Inc, Key Competitors 20
Flexion Therapeutics Inc, Ratios based on current share price 21
Flexion Therapeutics Inc, Annual Ratios 22
Flexion Therapeutics Inc, Annual Ratios (Cont...1) 23
Flexion Therapeutics Inc, Interim Ratios 25
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 28
Flexion Therapeutics Inc, Recent Deals Summary 29
Currency Codes 42
Capital Market Ratios 42
Equity Ratios 43
Profitability Ratios 43
Cost Ratios 44
Liquidity Ratios 44
Leverage Ratios 45
Efficiency Ratios 45

List of Figures
Flexion Therapeutics Inc, Performance Chart (2013 - 2017) 24
Flexion Therapeutics Inc, Ratio Charts 26
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 27
Flexion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 28

★調査レポート[Flexion Therapeutics Inc (FLXN):企業の財務・戦略的SWOT分析] (コード:DATA904C5338)販売に関する免責事項を必ずご確認ください。
★調査レポート[Flexion Therapeutics Inc (FLXN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆